Brief: Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
20/11/2024 13:57
Nov 20 (Reuters) - RenovoRx Inc RNXT.O :
* NORTHWELL HEALTH CANCER INSTITUTE LAUNCHES PATIENT
ENROLLMENT IN
RENOVORX’S ONGOING PIVOTAL PHASE III TIGER-PAC CLINICAL TRIAL
Source text: ID:nGNX423LKb
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer